When should I order a carbohydrate-deficient transferrin test and how do I interpret its results for assessing chronic heavy alcohol use?

Carbohydrate-Deficient Transferrin (CDT) Testing

CDT should not be used as a standalone screening test for chronic heavy alcohol use due to its poor sensitivity (25%-50%), but can serve as an adjunctive biomarker when combined with clinical assessment, validated questionnaires (AUDIT), and other alcohol biomarkers—particularly in patients without severe liver disease, normal body iron stores, and when monitoring treatment response. 1

When to Order CDT Testing

Primary Indications

• As an adjunct to diagnosis when clinical suspicion exists for chronic heavy alcohol consumption (≥50-80 g ethanol/day for 1-2 weeks minimum), combined with other laboratory tests and clinical interview 1, 2
• Monitoring treatment response in patients with established alcohol use disorder, where changes from individualized baseline values can detect relapse drinking 1, 3
• Post-liver transplant monitoring, where CDT appears more accurate due to improved liver function 1
• Differentiating alcohol-induced liver enzyme elevation from medication-induced enzyme elevation 2

When NOT to Order CDT

• Screening the general population for alcohol abuse—sensitivity is too low for this purpose 4, 2
• Patients with severe liver disease or cirrhosis—high false-negative rates occur due to impaired liver synthetic function 1, 5
• Patients with iron overload (including genetic hemochromatosis)—produces false-negative results 6
• Patients with iron deficiency—produces false-positive results 6
• As the sole confirmatory test—should never be used alone to confirm or refute alcohol use 1

Interpreting CDT Results

Understanding the Test

• Reported as %CDT (percentage of CDT per total transferrin) to account for individual variations in transferrin levels 1
• Half-life of 2-3 weeks—reflects drinking patterns over the preceding 2-3 weeks 1
• Normalizes 2-3 weeks after cessation of heavy drinking 7

Threshold Values

• Typical cutoff: %CDT >1.7 indicates heavy alcohol consumption 5
• Sensitivity: 25%-50% in most studies 1
• Specificity: Generally high when confounding factors are absent 2, 3

Factors Causing False-Negative Results

• Female gender—women may produce less CDT in response to heavy drinking 1, 3
• Obesity (BMI ≥25 kg/m² in Caucasians, ≥23 kg/m² in Asians)—independently associated with non-diagnostic CDT 5
• Cirrhosis or severe liver disease—impaired glycosylation capacity 1, 5
• Iron overload—significantly lowers CDT levels; false-negatives occur almost exclusively in patients with iron overload 6

Factors Causing False-Positive Results

• Iron deficiency anemia—significantly elevates CDT levels 6
• Congenital disorders of glycosylation (carbohydrate-deficient glycoprotein syndrome) 2
• Patients treated for galactosemia 2

Gender Considerations

• Women generally show lower CDT elevation for equivalent alcohol consumption compared to men 1, 3
• Baseline CDT values may be higher in women under natural conditions 3

Recommended Testing Algorithm

Step 1: Initial Screening

• Use validated questionnaires first: AUDIT score ≥8 (men up to age 60) or ≥4 (women, adolescents, men >60) indicates positive screen 4
• AUDIT-C: Score >4 (men) or >3 (women) warrants further evaluation 8

Step 2: Biomarker Selection

Prioritize phosphatidylethanol (PEth) over CDT for most clinical scenarios:

• PEth has superior sensitivity (88-100%) and specificity (77-96%) compared to CDT 1, 8
• PEth is not affected by liver disease, kidney disease, age, BMI, or sex 1, 8
• PEth detection window: 10-14 days for single episode, up to 6 weeks for chronic heavy use 8

Step 3: When to Add CDT

• Combine CDT with GGT and MCV when available—different pathophysiological mechanisms improve diagnostic value 2
• Use for longitudinal monitoring in treatment settings, tracking changes from individual baseline 1, 3
• Consider in post-transplant patients where accuracy improves 1

Step 4: Interpretation Context

• Never interpret CDT in isolation—must be combined with clinical interview, physical exam, and other laboratory testing 1
• Check iron studies before ordering CDT if results will influence clinical decisions 6
• Consider body mass index and gender when interpreting borderline results 5, 3

Superior Alternative Biomarkers

The 2025 Journal of Hepatology guidelines emphasize that whole blood PEth is now the preferred biomarker for monitoring alcohol use in clinical practice and liver transplant centers in the US and Europe 8

PEth Advantages Over CDT

• Higher sensitivity and specificity across all patient populations 1, 8
• Not affected by advanced liver disease—remains accurate in cirrhosis 1, 8
• Quantitative correlation with amount of alcohol consumed 8
• Optimal threshold: 18.5-20 ng/mL for detecting heavy alcohol use 8

Urinary Ethyl Glucuronide (EtG)

• Sensitivity 89%, specificity 99% in patients with alcohol-associated liver disease 1
• Detection window: up to 80 hours (3 days) after alcohol consumption 1, 7
• Useful for recent abstinence verification 7, 9

Common Pitfalls to Avoid

• Do not use CDT as a "gotcha" tool—discuss biomarker testing with patients beforehand to maintain therapeutic alliance 1
• Do not order CDT in cirrhotic patients expecting high sensitivity—false-negatives are common 1, 5
• Do not ignore body habitus—overweight/obese patients have significantly lower CDT sensitivity 5
• Do not overlook iron status—both iron overload and deficiency dramatically affect results 6
• Do not rely on CDT alone for diagnosis—American Society of Addiction Medicine recommends using biomarkers as aids to diagnosis and catalysts for discussion, not as standalone diagnostic tools 1